In the news release, Khiron Life Sciences to Webcast Live at VirtualInvestorConferences.com on January 30th, issued 28-Jan-2019 by VirtualInvestorConferences.com over PR Newswire, we are advised by the company that the presentation time below the first paragraph was incorrect and should read "10am EST" rather than "9:30am EST" as originally issued inadvertently. The complete, corrected release follows:
<!--Begin actual release body-->
TORONTO, Jan. 28, 2019 /PRNewswire/ -- Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that Khiron president Chris Naprawa will present live at VirtualInvestorConferences.com on January 30th, where he will discuss recent Company activity and the Latin American cannabis market.
DATE: Wednesday, January
30th
TIME: 10am
EST
LINK: https://tinyurl.com/0130prepr
This will be a live, interactive online event where investors are invited to ask Company executives questions in real-time - both in the presentation hall as well as the organization's virtual trade booth. If attendees are unable to join the event live on conference day, an archived webcast will also be made available after the event.
It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.VirtualInvestorConferences.com.
Recent Company Highlights
About Khiron
Khiron Life Sciences Corp. is
positioned to be the dominant integrated medical cannabis company
in Latin America. Khiron has core operations in
Colombia and is fully licensed in the country for the
cultivation, production, domestic distribution, and international
export of both THC (tetrahydrocannabinol) and CBD (cannabidiol)
medical cannabis. In May 2018, Khiron listed on the
TSX Venture Exchange, becoming one of the first Colombian based
medical cannabis companies to trade on any exchange globally.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/
Investor Contacts:
Chris Naprawa
President
T: +1 (416) 705-1144
E: [email protected]
Media Contact:
Jon Packer
Vice President, Communications
T: +1 (416) 543-9179
E: [email protected]
Cautionary Notes
Market and Industry Data
This press
release contains market and industry data and forecasts that were
obtained from third-party sources, industry publications and
publicly available information. Third-party sources generally state
that the information contained therein has been obtained from
sources believed to be reliable, but there can be no assurance as
to the accuracy or completeness of included information. Although
management believes it to be reliable, the Company has not
independently verified any of the data from third-party sources
referred to in this press release, or analyzed or verified the
underlying studies or surveys relied upon or referred to by such
sources, or ascertained the underlying economic assumptions relied
upon by such sources.
Forward-Looking Statements
This press
release may contain certain "forward-looking information" and
"forward-looking statements" within the meaning of applicable
Canadian securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Forward-looking statements may be identified by
statements containing the words "believes", "anticipates",
"plans", "intends", "will", "should", "expects", "continue",
"estimate", "forecasts" and other similar expressions.
Forward-looking statements herein include, but are not limited to,
statements regarding the final acceptance of the TSXV and the
commencement of sales in Mexico. Readers are cautioned
to not place undue reliance on forward-looking information. Actual
results and developments may differ materially from those
contemplated by these statements. Khiron undertakes no obligation
to comment analyses, expectations or statements made by
third-parties in respect of Khiron, its securities, or financial or
operating results (as applicable). Although Khiron believes that
the expectations reflected in forward-looking statements in this
press release are reasonable, such forward-looking statement has
been based on expectations, factors and assumptions concerning
future events which may prove to be inaccurate and are subject to
numerous risks and uncertainties, certain of which are beyond
Khiron's control, including the risk factors discussed in Khiron's
Annual Information Form which is available on Khiron's SEDAR
profile at www.sedar.com. The forward-looking information contained
in this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
View original content:http://www.prnewswire.com/news-releases/khiron-life-sciences-to-webcast-live-at-virtualinvestorconferencescom-on-january-30th-300785539.html